Generex Biotechnology

OverviewSuggest Edit

Generex Biotechnology Corporation is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.        

... Show more
TypePublic
HQBurlington, CAMap
Websitegenerex.com
Employee Ratings0More

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)3(-62%)
Revenue (FY, 2018)$703.2 K

Generex Biotechnology Office Locations

Generex Biotechnology has an office in Burlington
Burlington, CA (HQ)
4145 N Service Rd
Show all (1)
Report incorrect company information

Generex Biotechnology Financials and Metrics

Generex Biotechnology Revenue

Generex Biotechnology's revenue was reported to be $703.24 k in FY, 2018
USD

Revenue (Q1, 2019)

1.7m

Gross profit (Q1, 2019)

848.5k

Gross profit margin (Q1, 2019), %

49.4%

Net income (Q1, 2019)

17.8m

EBIT (Q1, 2019)

(1.6m)

Cash (31-Oct-2018)

2.4m

EV

32.5m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

703.2k

General and administrative expense

3.0m2.7m1.4m1.2m2.4m

R&D expense

1.4m1.2m467.4k422.3k839.1k

Operating expense total

4.4m3.9m1.9m1.6m3.2m
Quarterly
USDQ3, 2014Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

2.2k700.0k702.2k1.7m

Cost of goods sold

870.6k

Gross profit

848.5k

Gross profit Margin, %

49%
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

3.3m750.0k16.9k2.9m1.0m

Accounts Receivable

980.033.6k

Inventories

10.0k12.1k

Current Assets

3.5m801.2k25.0k2.9m1.2m
Quarterly
USDQ3, 2014Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

4.2m52.4k31.8k47.2k37.1k2.3m2.0m1.6m2.4m

Accounts Receivable

175.0175.03.0m

Inventories

22.7k12.0k12.0k12.0k838.7k

Current Assets

4.3m104.4k36.9k55.3k4.1m2.6m2.3m1.7m6.4m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(1.4k)(2.2m)(3.2m)35.9m

Depreciation and Amortization

368.4k380.7k265.2k5.0k23.8k

Inventories

11.1k(2.0k)

Accounts Payable

(490.4k)(117.7k)1.1m899.8k872.2k
Quarterly
USDQ3, 2014Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(2.4m)27.5m17.7m21.1m17.8m

Depreciation and Amortization

280.7k52.7k123.1k194.2k2.3k1.2k2.0k17.5k25.7k

Inventories

(1.6k)(2.0k)(2.0k)(2.0k)242.2k

Accounts Payable

(300.4k)522.1k662.8k823.7k592.6k318.0k211.7k673.9k1.0m
show all
USDY, 2018

EV/EBIT

-20.3 x

EV/CFO

-91.1 x

Financial Leverage

-0.8 x
Show all financial metrics
Report incorrect company information

Competitors

Opiant Pharmaceuticals
Healthcare - Public
IntelGenx
Healthcare - Public
Adamas Pharmaceuticals
Healthcare - Public
E-Therapeutics
Healthcare - Public
Compare competitors

Generex Biotechnology Online and Social Media Presence

Embed Graph
Report incorrect company information

Generex Biotechnology News and Updates

February 19, 2019

Generex Biotechnology Subsidiary Regentys Corporation Receives Approval of Japanese Patent for Extracellular Matrix Hydrogel (Regentys ECMH(TM))

MIRAMAR, FL - (NewMediaWire) - February 19, 2019 - Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company’s subsidiary Regentys Corporation, a clinical stage regenerative medicine company focused on the …
February 15, 2019

Generex Biotechnology Announces Investor Conference Call Agenda; Tuesday, February 26, at 11:00 A.M. Eastern

Management to Provide Update on Strategic Acquisitions, Financing, Growth Initiatives & Spin Out of NuGenerex Immuno-Oncology MIRAMAR, FL - (NewMediaWire) - February 15, 2019 - Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), toda…
February 04, 2019

Generex Biotechnology Responds to Demand for Payment

- Challenges notice from Alpha Capital
January 29, 2019

Generex Biotechnology Announces Investor Conference Call Scheduled for February 26, 2019

Management to Provide Details on NuGenerex Immuno-Oncology: Dividend, New Acquisitions, IP Licensing Opportunities, and Strategic Plans for Public Listing Acquisition, Integration of Fuse Medical, Pantheon Medical, and MediSource Partners, and Additional Acquisitions Financing Initiatives & …
January 22, 2019

Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans

Acquisitions, Financing, Expansion Initiatives & Strategic Plans MIRAMAR, FL - (NewMediaWire) - January 22, 2019 - Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is happy to provide the investment community with a review of the ma…
January 08, 2019

Generex Biotechnology Completes Acquisition of Olaregen Therapeutix Inc.

- Closes transaction to complete 51% acquisition of Olaregen Therapeutix
Show more
Report incorrect company information

Generex Biotechnology Company Life and Culture

Report incorrect company information

 Generex Biotechnology Frequently Asked Questions

  • How many employees does Generex Biotechnology have?

    Generex Biotechnology has 3 employees.

  • What is Generex Biotechnology revenue?

    Latest Generex Biotechnology annual revenue is $703.2 k.

  • What is Generex Biotechnology revenue per employee?

    Latest Generex Biotechnology revenue per employee is $234.4 k.

  • Who are Generex Biotechnology competitors?

    Competitors of Generex Biotechnology include Opiant Pharmaceuticals, IntelGenx and Adamas Pharmaceuticals.

  • Where is Generex Biotechnology headquarters?

    Generex Biotechnology headquarters is located at 4145 N Service Rd, Burlington.

  • Where are Generex Biotechnology offices?

    Generex Biotechnology has an office in Burlington.

  • How many offices does Generex Biotechnology have?

    Generex Biotechnology has 1 office.